ALL-I-0143

What is Sepsis?

Sepsis develops when initial immune responses to invasive pathogens become uncontrolled and cause often fatal "cytokine storms." Sepsis remains a leading cause of death in ICUs worldwide with about 1.5 million recorded cases each year in the United States alone. GlobalData projects sepsis and septic shock space growth from $2.8 billion to $5.9 billion by 2026.

Mode of Action

ALL-I-0143 is a bispecific nanoantibody drug that contains three tumor necrosis factor alpha (TNFα) binding modules. TNFα is a key protein involved in promoting systemic inflammation. Inhibition of TNFα has shown an immunosuppresive effect in addition to an overall reduction in inflammation.

Back to list -->